Latest Hotspot

InnoCare Reveals approval of the Clinical Experiment for ICP-189, Coupled with EGFR Inhibitor Furmonertinib

19 September 2023
3 min read

InnoCare Pharma, a prominent biopharmaceutical corporation specializing in cancer and autoimmune disease therapies, has revealed today that it has received IND approval to carry out a clinical study in China. This trial will examine the effects of a new SHP2 allosteric inhibitor, ICP-189 , in conjunction with furmonertinib, an EGFR inhibitor known for its high brain penetration and broad mutation-specific activity.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

In the middle of July, a clinical development partnership was unveiled by InnoCare and ArriVent. The aim was to examine the anti-cancer properties and safety of the combination of furmonertinib and ICP-189 in people battling with advanced non-small cell lung cancer.

ArriVent is progressing with global research on furmonertinib for patients with advanced or metastatic NSCLC with EGFR or HER2 mutations. This includes those with exon 20 insertion mutations and other rare EGFR mutations. It has been given approval in China for first-line treatment for adults afflicted with locally advanced or metastatic NSCLC possessing EGFR exon 19 deletion or exon 21 substitution mutations.

A dosage escalation study revealed that the dosage has successfully been escalated to 120mg with no observed DLT, and a favorable safety and PK profile has been exhibited. Initial efficacy was seen in ICP-189 as a monotherapy. In the 20mg dosage cohort, a patient suffering from cervical cancer achieved a confirmed partial response.

InnoCare's Co-Founder, Chairwoman, and CEO, Dr. Jasmine Cui voiced that the SHP2 inhibitor is the optimal partner for combinational use with various targeted and immune-oncology therapies in the realm of solid tumors. She stated that ICP-189 has shown remarkable anti-tumor efficacy in tumor models driven by KRASG12C mutation or EGFR over-production. InnoCare plans to collaborate with ArriVent to expedite the clinical development of the ICP-189 and furmonertinib combination. This innovative treatment is intended to assist patients with advanced NSCLC at an earlier stage.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 18, 2023, there are 34 investigational drugs for the SHP2 target, including 30 indications, 54 R&D institutions involved, with related clinical trials reaching 66and as many as 3117 patents.

ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents. It targets SHP2 and is indicated for the treatment of solid tumors and EGFR-mutated non-small cell lung cancer. ICP-189 shows promise in the field of biomedicine for potential therapeutic interventions in neoplasms and respiratory diseases.

图形用户界面, 文本, 应用程序

描述已自动生成

Strategy for Retrieving Bispecific Antibody Sequences
Bio Sequence
2 min read
Strategy for Retrieving Bispecific Antibody Sequences
19 September 2023
Using the Patsnap Bio Sequence Database for bispecific antibody sequence retrieval is recommended.
Read →
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
Latest Hotspot
3 min read
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
19 September 2023
Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.
Read →
"Super drugs" for treating cancer and AIDS: Chemokines family
Advanced Tech.
10 min read
"Super drugs" for treating cancer and AIDS: Chemokines family
19 September 2023
Chemokines, also known as chemotactic cytokines, are a group of factors that, in conjunction with their cell surface receptors, induce the directed migration of leukocytes.
Read →
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
Latest Hotspot
4 min read
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
19 September 2023
NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.